Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

494

Participants

Timeline

Start Date

May 7, 2020

Primary Completion Date

October 2, 2023

Study Completion Date

June 19, 2026

Conditions
Multiple Myeloma
Interventions
DRUG

Belantamab mafodotin

Humanized anti-B-cell maturation antigen (BCMA) antibody/drug conjugate

DRUG

Daratumumab

Anti-cluster of differentiation 38 \[CD-38\] monoclonal antibody

DRUG

Bortezomib

Proteasome Inhibitor

DRUG

Dexamethasone

Synthetic glucocorticoid with anti-tumor activity

Trial Locations (144)

1090

GSK Investigational Site, Brussels

1200

GSK Investigational Site, Brussels

1309

GSK Investigational Site, Takapuna Auckland

2050

GSK Investigational Site, Camperdown

2065

GSK Investigational Site, St Leonards

2170

GSK Investigational Site, Liverpool

2298

GSK Investigational Site, Waratah

2500

GSK Investigational Site, Wollongong

3004

GSK Investigational Site, Melbourne

3084

GSK Investigational Site, Heidelberg

3128

GSK Investigational Site, Box Hill

4029

GSK Investigational Site, Herston

4217

GSK Investigational Site, Benowa

5037

GSK Investigational Site, Ashford

6009

GSK Investigational Site, Nedlands

6021

GSK Investigational Site, Wellington

6150

GSK Investigational Site, Murdoch

8011

GSK Investigational Site, Christchurch

8800

GSK Investigational Site, Roeselare

9000

GSK Investigational Site, Ghent

9054

GSK Investigational Site, Dunedin

10003

GSK Investigational Site, Cáceres

10126

GSK Investigational Site, Torino

11528

GSK Investigational Site, Athens

13620

GSK Investigational Site, Seongnam-si Gyeonggi-do

14033

GSK Investigational Site, Caen

20133

GSK Investigational Site, Milan

24014

GSK Investigational Site, Roanoke

24127

GSK Investigational Site, Bergamo

25123

GSK Investigational Site, Brescia

28007

GSK Investigational Site, Madrid

28223

GSK Investigational Site, Pozuelo de AlarcOn Madr

28933

GSK Investigational Site, MOstoles Madrid

30008

GSK Investigational Site, Murcia

30510

GSK Investigational Site, Krakow

31008

GSK Investigational Site, Madrid

GSK Investigational Site, PamplonaNavarra

33394

GSK Investigational Site, Gijón

35033

GSK Investigational Site, Rennes

37007

GSK Investigational Site, Salamanca

40138

GSK Investigational Site, Bologna

40225

GSK Investigational Site, Düsseldorf

44033

GSK Investigational Site, Ulsan

44281

GSK Investigational Site, Kfar Saba

45242

GSK Investigational Site, Fairfield

47014

GSK Investigational Site, Meldola FC

48121

GSK Investigational Site, Ravenna

49241

GSK Investigational Site, Pusan

50937

GSK Investigational Site, Cologne

52621

GSK Investigational Site, Tel Litwinsky

53100

GSK Investigational Site, Siena

54007

GSK Investigational Site, Thessaloniki

64239

GSK Investigational Site, Tel Aviv

66205

GSK Investigational Site, Kansas City

75651

GSK Investigational Site, Paris

75702

GSK Investigational Site, Tyler

80054

GSK Investigational Site, Amiens

80218

GSK Investigational Site, Denver

81377

GSK Investigational Site, München

85364

GSK Investigational Site, Yuma

89081

GSK Investigational Site, Ulm

91120

GSK Investigational Site, Jerusalem

95123

GSK Investigational Site, Catania

97080

GSK Investigational Site, Würzburg

100020

GSK Investigational Site, Beijing

100191

GSK Investigational Site, Beijing

110001

GSK Investigational Site, Shenyang

125284

GSK Investigational Site, Moscow

130012

GSK Investigational Site, Changchun

191024

GSK Investigational Site, Saint Petersburg

210008

GSK Investigational Site, Nanjing

215006

GSK Investigational Site, Suzhou

250012

GSK Investigational Site, Jinan

300020

GSK Investigational Site, Tianjin

310003

GSK Investigational Site, Hangzhou

410028

GSK Investigational Site, Saratov

443021

GSK Investigational Site, Samara

450052

GSK Investigational Site, Zhengzhou

450083

GSK Investigational Site, Ufa

510060

GSK Investigational Site, Guangzhou

510515

GSK Investigational Site, Guangzhou

603126

GSK Investigational Site, Nizhny Novgorod

630087

GSK Investigational Site, Novosibirsk

22775001

GSK Investigational Site, Rio de Janeiro

88020-210

GSK Investigational Site, Florianópolis

89201-260

GSK Investigational Site, Joinville

59075-740

GSK Investigational Site, Natal

90035-903

GSK Investigational Site, Porto Alegre

04537-080

GSK Investigational Site, São Paulo

05403-000

GSK Investigational Site, São Paulo

T6G 1Z2

GSK Investigational Site, Edmonton

N6A 5W9

GSK Investigational Site, London

M4N 3M5

GSK Investigational Site, Toronto

H4J 1C5

GSK Investigational Site, Montreal

G1J 1Z4

GSK Investigational Site, Québec

625 00

GSK Investigational Site, Brno

500 05

GSK Investigational Site, Hradec Králové

708 52

GSK Investigational Site, Ostrava

128 08

GSK Investigational Site, Prague

06200

GSK Investigational Site, Nice

07747

GSK Investigational Site, Jena

68 100

GSK Investigational Site, Alexandroupoli

00168

GSK Investigational Site, Roma

441-8570

GSK Investigational Site, Aichi

467-8602

GSK Investigational Site, Aichi

030-8553

GSK Investigational Site, Aomori

790-8524

GSK Investigational Site, Ehime

806-8501

GSK Investigational Site, Fukuoka

807-8555

GSK Investigational Site, Fukuoka

810-8563

GSK Investigational Site, Fukuoka

815-8555

GSK Investigational Site, Fukuoka

503-8502

GSK Investigational Site, Gifu

377-0280

GSK Investigational Site, Gunma

670-8540

GSK Investigational Site, Hyōgo

221-0855

GSK Investigational Site, Kanagawa

247-8533

GSK Investigational Site, Kanagawa

781-8555

GSK Investigational Site, Kochi

392-8510

GSK Investigational Site, Nagano

701-1192

GSK Investigational Site, Okayama

530-0012

GSK Investigational Site, Osaka

545-8586

GSK Investigational Site, Osaka

411-8777

GSK Investigational Site, Shizuoka

3318 AT

GSK Investigational Site, Dordrecht

9713 GZ

GSK Investigational Site, Groningen

41-500

GSK Investigational Site, Chorzów

93-513

GSK Investigational Site, Lodz

20-081

GSK Investigational Site, Lublin

20-090

GSK Investigational Site, Lublin

33-300

GSK Investigational Site, Nowy Sącz

60-569

GSK Investigational Site, Poznan

02-781

GSK Investigational Site, Warsaw

197 089

GSK Investigational Site, Saint Petersburg

06351

GSK Investigational Site, Seoul

06591

GSK Investigational Site, Seoul

08035

GSK Investigational Site, Barcelona

08916

GSK Investigational Site, Barcelona

08908

GSK Investigational Site, L'Hospitalet de Llobrega

BH7 7DW

GSK Investigational Site, Bournemouth

CF14 4XW

GSK Investigational Site, Cardiff

DD1 9SY

GSK Investigational Site, Dundee

LE1 5WW

GSK Investigational Site, Leicester

W12 0NN

GSK Investigational Site, London

ST4 6QG

GSK Investigational Site, Stoke-on-Trent

SM2 5PT

GSK Investigational Site, Sutton

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT04246047 - Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter